Among the strong points of Nektar Therapeutics Inc.’s atopic dermatitis (AD) prospect, rezpegaldesleukin (rezpeg), an IL-2 pathway agonist and regulatory T-cell proliferator, is the drug’s faster onset of action – a feature that experts say may help differentiate the compound from competitors in the OX40 space.

The fibroblast growth factor 21 (FGF21) analogue space took another turn as Novo Nordisk A/S said during its second-quarter financial update that work with zalfermin (NNC0194-0499) will be discontinued. A phase II study testing the compound in combination with glucagon-like peptide-1 therapy failed to hit the primary endpoint related to liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), without MASH worsening.

The autoimmune disorder systemic lupus erythematosus (SLE) involves upregulation of IgD, and studies have shown that anti-IgD antibodies can alleviate the autoimmune disorder rheumatoid arthritis in mouse models. Building on this finding, researchers in Hefei and Changshu, China, have shown that interrupting the interaction between IgD and its receptor FcδR can reduce cytokine levels and phosphorylation of JAK2 and STAT3, suppressing the activation and proliferation of CD4+ T cells in SLE.

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s neuroimmunology portfolio.

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s neuroimmunology portfolio.

Researchers at Caedo Oncology AS and collaborators have recently developed a new chimeric bifunctional anti-CD47 (IgG4) fusion protein, CO-001, and its optimized variant CO-005, a bivalent humanized single-chain fragment variable-fragment crystallizable fusion protein, which exhibited potent anti-cancer activity through a dual mechanism of action.

Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private placement in public equity financing and inking a new $4.23 billion license deal for Yantai Rongchang Biotechnologies (Remegen) Co. Ltd.’s telitacicept, a dual-target fusion protein drug approved in China for three autoimmune indications. The news was disclosed after U.S. market hours June 25. Vor’s shares (NASDAQ:VOR) gained 34 cents, or 60.5%, to close June 26 at 89 cents. The company’s shares had risen for eight consecutive trading days since June 17.

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive global rights to a preclinical claudin 3-targeting monoclonal antibody, ABN-501, and the potential to license four more protein targeting antibodies.